Ravi Vij MD MBA

Hematologic Oncology

PROFESSOR OF MEDICINE, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

4500 Forest Park AveDiv IM Bone Marrow Transplant 5TH 6TH 8TH FLSt. Louis, MO 63108
Phone+1 314-454-8304
Fax+1 314-454-5902

Dr. Vij is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Vij's full profile Already have an account?

Education & Training

George Washington UniversityMBA, Business administration, 2011 - 2013
WashU Medicine2000
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1999
Rush University Medical CenterResidency, Internal Medicine, 1996
Maulana Azad Medical CollegeClass of 1990

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

IL State Medical License 2020 - 2029
MO State Medical License 1996 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013-2017
CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2013-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR (Modular), Allscripts, 2013-2017

Clinical Trials

Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission
COMPLETED
PHASE2
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma
TERMINATED
PHASE2
Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
TERMINATED
PHASE3

Publications & Presentations

PubMed

The association between allostatic load and monoclonal gammopathy of undetermined significance (MGUS).
Mark A Fiala, Tuo Lan, Michael J Slade, Ravi Vij, Su-Hsin Chang
British Journal of Haematology. 2026-07-27
A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma.
Hans C Lee, Wouter J Plattel, Simon J Harrison, Douglas W Sborov, Suzanne Lentzsch
Blood. 2026-07-09
Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/ refractory multiple myeloma treated in Europe.
Michele Cavo, Fredrik Schjesvold, Meletios Dimopoulos, Michel Delforge, Fernando Escalante
Haematologica. 2026-07-01

Journal Articles

Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation
M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature

Abstracts/Posters

Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Ravi Vij, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Relapsed/Refractory Multiple Myeloma: Current Treatment and Emerging Approaches
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Practical Use of Imaging From MGUS to Myeloma
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Investigational Drug May Improve Stem Cell Transplantation for Multiple Myeloma PatientsApril 17th, 2023
Karyopharm’s Selinexor Combination for Multiple Myeloma Unlikely to See Second-Line Use Despite Likely FDA ApprovalDecember 18th, 2020
Vij Highlights Benefits of Quadruplet Therapy for Patients with Multiple MyelomaDecember 13th, 2019